Release Date: Monday, June 30, 2014
Expiration Date: Tuesday, June 30, 2015
Format: Downloadable, text-based monograph
Estimated Time To Complete Activity: 15 minutes  

  

The Clinical Coffee Break is a 0.25 hour CME-certified activity designed to fit a busy clinician’s need to quickly gain specific knowledge during their hectic practice schedule. This particular activity will be in the form of an expert interview with one clinician interviewing another and a full transcript provided as an approximately 1,500-word activity. This format is ideal for summarizing a large body of research and provides expert opinion/thought leader insight into the implications it has on patient care.

Activity Overview
Several new classes of diabetes drugs have been approved in the United States in the last ten years. With a surge of new medications available for the pharmacologic management of type 2 diabetes, the clinician is faced with choosing appropriate patient-centered therapies to effectively control glucose and minimize adverse effects. After medications are approved and made available for use, information continues to emerge from further research studies and post-marketing data.

Clinical practice guidelines, developed by professional organizations and practice experts, are often not revised and disseminated at the same rate as new research becomes available through medical literature and new drugs are released. The clinician must interpret research articles to determine if and how they affect current practice guidelines or how new drug therapies fit into existing guidelines. Using evidence-based medicine (EBM) involves using the best evidence available to guide clinical decisions. Interpreting and understanding the evidence is a valuable skill for medical providers.

Target Audience
This educational activity is intended for primary care clinicians, endocrinologists and other healthcare professionals who provide care to patients with diabetes.

Activity Goal
The goal of this activity is to provide clinicians with appropriate data and its clinical relevance to practice, using the latest evidence-based literature on current and emerging therapies for the treatment of patients with type 2 diabetes.

Learning Objectives
At the conclusion of this activity, participants should be able to:

  • Recognize the importance of keeping up with current medical literature for diabetes therapies and its application to clinical practice
  • Define evidence-based medicine (EBM) and review key aspects of a recent article on new and emerging therapies


Faculty
John E. Anderson, MD

The Frist Clinic
Immediate Past President, Medicine and Science
American Diabetes Association
Nashville, Tennessee

Moderator
Holly Divine, PharmD, BCACP, CGP, CDE, FAPhA

Clinical Associate Professor
University of Kentucky College of Pharmacy
Co-founder, PharmacistCARE Medication Therapy Management Service
Lexington, Kentucky

Accreditation Statement
This activity has been planned and implemented by Creative Educational Concepts, Inc. (CECI), AXIS Medical Education, Inc., and MedPage Today for the advancement of patient care. CECI is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the healthcare team.

Credit Designation
CECI designates this enduring material educational activity for a maximum of 0.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Participation
To receive a statement of credit, you must: 

  • Review the full content of the activity.
  • Successfully complete the post-test (75% or better).
  • Complete the evaluation at the end of the activity.
  • Statements of credit will be issued immediately online upon successful completion of the post-test/evaluation.


Disclosure Declaration
It is the policy of CECI to ensure independence, balance, objectivity, scientific rigor, and integrity in their continuing education activities.

Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.

Fair balance is achieved through ongoing and thorough review of all presentation materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by CECI for any product or manufacturer identified.

CECI has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

John Anderson, MD
Dr. Anderson has disclosed that he is a consultant for Janssen Pharmaceuticals, Lilly, and sanofi-aventis. He is a member of the speakers’ bureaus for AstraZeneca, Boehringer-Ingelheim, and Janssen Pharmaceuticals.

Holly Divine, PharmD, BCACP, CGP, CDE, FAPhA
Dr. Divine has no financial relationships to disclose in relation to the content of this activity.

The planners and managers have no financial or other relationship to products or devices with commercial interests related to the content of this CME activity.

Policy on Unlabeled/Off-Labeled Use
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Fee
There is no fee to participate in this educational activity.

Disclaimer
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of  Creative Educational Concepts, Inc. 

Jointly Provided by:
Creative Educational Concepts, Inc., AXIS Medical Education, Inc., and MedPage Today

This activity is supported by an educational grant from Merck.